Anti-Mensing Bill Could Topple FDA's Generics Framework

Law360, New York (April 20, 2012, 7:37 PM EDT) -- A proposed bill that would allow generic-drug makers to change their own safety labels — an effort to open generics companies to failure-to-warn suits after the Supreme Court found last year that such suits are preempted — could undermine the entire regulatory system for generics, experts say.

The bill seeks to address what its lead sponsor, Sen. Patrick Leahy, D-Vt., calls a “troubling inconsistency” opened up by the court's decision in Pliva v. Mensing. Plaintiffs can no longer sue generic drugmakers for product liability claims tied...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.